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Calcitonin gene-related peptide (CGRP) receptor activity was studied in WE-68 human Ewing’s sarcoma cells. iZSI-human 
CGRP bound in a time~~ndent, reversible and saturable manner. Scatchard plots were compatible with the presence 
of a homogenous population of CGRP receptors with high affinity (& = 15 PM, and S,,, = 1.9 fmol/mg protein). 
The potency order of unlabeled peptides, in the presence of radioligand, was: human CGRP-II > human CGRP = chick 
CGRP > rat CGRP = rat [TyIO]CGRP > human pylo] CGRP >> salmon calcitonin (CT) > rat [TyrO]CGRP-(28-37). 
Each peptide except CT and [TyP]CGRP-(28-37) stimulated cyclic AMP generation in a concentration-dependent man- 
ner, and the relative potencies paralleled their relative ability in inhibiting *ZSI-human CGRP binding. We conclude that 
WE-68 Ewing’s sarcoma cells express genuine CGRP receptors which upon activation lead to stimulation of cyclic AMP 
formation. 
Calcitonin gene-related peptide; Calcitonin; cyclic AMP; (Human; Ewing’s sarcoma cell) 
1. INTRODUCTION 
Calcitonin gene-related peptide (CGRP; CGRP- 
I; CV-CGRP) is a recently discovered 37-amino-acid 
polypeptide which is generated by tissue-specific 
alternative calcitonin gene transcription f 1,2]. The 
mRNA transcripts of the calcitonin gene encode 
calcitonin (CT) in thyroid C-cells, and CGRP in 
human ventral spinal cord, thyroid, pituitary, and 
in medullary thyroid carcinoma cells [3-51. A 
structurally related second human gene, which is a 
pseudogene for CT, generates CGRP-II (a-CGRP) 
that differs from human CGRP-I in 3 of 37 amino 
acids [4]. Radioreceptor assay and immunological 
studies have demonstrated discrete binding sites 
for CGRP and CT in the human and rat central 
nervous system and peripheral tissues [5,6]. 
Nonetheless, because of structural similarities bet- 
ween the two peptides (a disulfide bond in the N- 
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terminus; an amidated C-terminus) CGRP and CT 
have been shown to cross-react with the high- 
affinity binding site of the other [6,7]. Although 
the central nervous system expresses predominant- 
ly CGRP receptors no influence of CGRP on the 
cyclic AMP-generating system was observed [6] 
whereas the kidney-adenylate cyclase was 
stimulated by CGRP through interaction with 
functional CT receptors [6,7]. 
WE-68 is a human Ewing’s bone tumor cell line 
which expresses morphological features of 
neuroectoderm~ differentiation, namely neuron- 
specific enolase, S-100 protein, Leu-7-antigen and 
neurofilaments 181. Furthermore, WE-cells res- 
pond to various neurohormones including ,B- 
adrenergic agonists, dopamine, vasoactive in- 
testinal peptide, neuropeptide Y, by a modulation 
of cyclic AMP metabolism [g-12]. On the basis of 
these data the possibility was examined whether 
the neuropeptide CGRP might interact with 
WE-68 cells. Our study shows that WE-68 cells 
possess specific CGRP receptors and is the first 
demonstration of functional CGRP receptors in 
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cultured cells of human nature, with neural dif- 
ferentiation potential. 
2. MATERIALS AND METHODS 
Human, chick and rat CGRP, human CGRP-II, human and 
rat [Tyr’]CGRP, rat [TyrqCGRP-(28-37), human and salmon 
CT, human vasoactive intestinal peptide (VIP) and human 
neuropeptide Y (NPY) were purchased from Peninsula (St. 
Helens, England). Monoiodinated ‘2SI-His’o-human CGRP 
(‘?-human CGRP; 2ooO Ci/mmol) was obtained from Amer- 
sham (Braunschweig) and 3-isobutyl-l-methy~anthine (IBMX) 
from Sigma (Munich). 
Ewing’s sarcoma WE-68 cells were cultured in Dulbecco’s 
modified Eagle’s medium/Ham’s Formula-12 (I: 1; DME/FlZ) 
with 5% FCS and maintained in fibronectin-coated 
(0.5 pg/cm’; Boehringer, Mannheim) Falcon T-25 flasks [9]. 
“‘1-CGRP binding and cyclic AMP production experiments 
were conducted on fibronectin-coated (0.5 pg/cm’) Costar 
24-well dishes seeded with 4 x 10’ cells/well. 
To study ‘*‘I-CGRP binding, confluent cultures were in- 
cubated in DME/F12 (1 : 1) containing 1% (w/v) human serum 
albumin (HSA) and varying concentrations of 12s1-human 
CGRP (2.3-86.9 PM) in the absence (total binding) and 
presence (nonspecific binding) of unlabeled human CGRP 
(ZOO nM) in a total volume of 300 ~1 at 37°C for 150 min. Cell- 
associated radioactivity was determined in an LKB 1270 
Rackgamma- y-counter after cell lysis with Lubrol-PX (I%, 
v/v)/HSA (1 To) in Hz0 as described [IO]. 
Incubation of monolayer cell cultures to study cyclic AMP 
formation was carried out as in [ll]. In short, cells were in- 
cubated for IS min at 37’C with peptide in Hank’s buffer with 
20 mM Hepes (pH 7.4) after a 15-min preincubation period in 
this buffer containing 1 mM IBMX. Cyclic AMP samples were 
treated according to the trichioroacetic acid/Tris protocol [12] 
and determined with the Amersham assay kit. Cell protein was 
measured by the Bio-Rad protein assay (Bio-Rad, Munich) 
using HSA as standard. 
Data are expressed as means + SE of triplicate determina- 
tions from three experiments in each case. Binding data were 
analyzed by the computer COMBICEPT 2000 CA receptor 
assay program from Canberra-Packard (Frankfurt~. 
3. RESULTS 
The association of 1251-human CGRP with intact 
human Ewing’s sarcoma WE-68 cells reached 
equilibrium after 120-150 min at 37”C, and was 
reversed within 100 min in the absence and 
presence of unlabeled human CGRP (fig.1). 
Binding of radioligand was concentration- 
dependent (fig.2). Specific binding averaged 75% 
of total 12%human CGRP bound, which 
represented 4-6070 of total radioactivity added to 
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Fig. 1. Association-dissociation pattern for the binding of “‘I-human CGRP in WE-68 cells. Cells were incubated at 37°C in the 
presence of 150 pM “‘I-human CGRP alone (0, total binding) or with excess human CGRP (200 nM) (D, nonspecific binding); 
120 min later cells were reincubated in binding medium alone (e) or supplemented with human CGRP (A ; 200 nM). Values are 
means + SE from 3 independent experiments. 
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Fig.2. Saturation isotherm obtained from incubating WE-68 
cells for 150 min at 37’C with increasing concentrations of ‘% 
human CGRP alone (O---O) or in the presence of 200 nM 
human CGRP (O---O). Specific ‘251-human CGRP binding (0) 
was calculated as the difference between the total and 
nonspecific radioactivity associated to the cells. Values are 
means + SE from 3 independent experiments. Inset: Scatchard 
plot of ‘%human CGRP specific binding data. 
the culture wells containing 140-160,~g cell pro- 
tein. Scatchard plot analysis of ‘251-human CGRP 
steady-state binding data gave a straight line (fig.2, 
inset). The dissociation constant (&) was 
calculated to be 15 pM, and maximal binding 
capacity (B,,, ), 1.9 fmol/mg cell protein. As 
shown in fig.3, radioligand binding was inhibited 
by human CGRP-II (half-maximal inhibitory con- 
centration [IC~O] = 20 PM), human and chick 
CGRP (ICsos = 100 PM), rat CGRP and 
[Tyr’]CGRP (IC~OS = 200 PM) and human 
[Tyr’]CGRP (I& = 1 nM). Salmon CT was 
50000 times less potent than human CGRP-II, and 
the C-terminal fragment [Tyr’]CGRP-(28-37) at 
1 ,&I inhibited binding of tt51-human CGRP by 
07, -13 -1z -11 -10 AgonTsst conz2”trat-~o” ,MP 
Fig.3. Displacement of ‘2SI-human CGRP binding in WE-68 
cells incubated for 150 min at 37°C with 100 pM tracer in the 
presence of increasing concentrations of human CGRP-II (o), 
chick CGRP (A), human CGRP (vf, rat CGRP (elf), rat 
[Tyr’lCGRP (o), human [Tyr“]CGRP (A), salmon CT (o), rat 
[Tyr’]CGRP-(28-37) (v), human CT (a), VIP (B), and NPY 
(*) expressed as percentage of “‘I-human CGRP binding in the 
absence of added peptide. Values are means + SE from 3 
independent experiments. 
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Fig.4. Time course of cyclic AMP production in WE-68 cells 
incubated in the presence of 200 nM human CGRP without 
(open symbols) and with (closed symbols) 1 mM IBMX. Basal 
cyclic AMP levels (nmol/mg of protein) were 0.14 + 0.03 (in the 
absence of IBMX) and 0.29 * 0.02 (in the presence of IBMX) 
for the indicated time periods, and were subtracted from the 
appropriate peptide-stimuiated cyclic AMP levels. Values are 
means f SE from three independent experiments. 
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30%. Tracer binding was not displaced by human 
CT, VIP and NPY at up to 1 PM. 
Human CGRP provoked a curvilinear increase 
in the cyclic AMP content in WE-68 cells (fig.4). 
The stimulation was noticeable as early as 2.5 min 
after addition of the peptide and peaked between 
60 and 90 min which corresponded with a 30-fold 
increase over the basal. The course of the time 
curve was the same as that observed in the absence 
of the phosphodiesterase inhibitor IBMX, but 
under these conditions the peptide raised cyclic 
AMP levels by maximally g-fold. The 
concentration-effect curves for cyclic AMP 
generation by CGRPs and CTs are depicted in 
fig.5. Human CGRP-II was the most potent pep- 
tide stimulating cyclic AMP already significant at 
0.5 nM (fig.SA) with half-maximal effective con- 
centration (E&J of 1.5 nM human CGRP-II. 
Human and chick CGRP were as efficient as 
human CGRP-II but were each approx. 4-fold less 
potent (E&s = 6 nM); CGRP and [Tyr’]CGRP 
of rat were each lo-fold less potent than human 
CGRP-II (ECsos = 15 nM). The potency of human 
[Tyr’]CGRP was 40-fold lower than that of human 
CGRP-II (EC50 = 60 nM). Rat [Tyr’]CGRP- 
(28-37) as high as 1 PM caused no increase in 
cellular cyclic AMP content and was unable to 
modify rat CGRP action (fig.SB). Salmon CT in- 
creased cyclic AMP marginally (1.6-fold over the 
basal) but significantly (P < 0.05) only at a very 
high (1 PM) concentration, and human CT was in- 
active in raising cyclic AMP levels (fig.SA). 
4. DISCUSSION 
Our results demonstrate the existence of func- 
tional CGRP receptors in WE-68 human Ewing’s 
sarcoma cells. ‘251-human CGRP bound in a time- 
dependent and reversible manner with a single 
class of receptors that were saturable (B,, = 
1.9 fmol/mg cell protein) and of high affinity 
(& = 15 PM). The specificity of the CGRP recep- 
tor was shown by its selectivity towards a series of 
CGRPs and CTs tested on 1251-human CGRP bin- 
ding and cyclic AMP generation: human CGRP- 
II > chick CGRP = human CGRP > rat CGRP = 
rat [Tyr’]CGRP > human [Tyr’]CGRP *, salmon 
CT, implying CGRP receptors predominate in 
WE-68 cells and CT most probably interacts with 
these CGRP receptors. Specific high-affinity 
CGRP receptors (& Values ranging from 4 to 
85 PM) have been observed with membranes from 
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Fig.5. Cyclic AMP production in WE-68 cells incubated with increasing concentrations of human CGRP-II (0), chick CGRP (A), 
human CGRP (v), rat CGRP (O), rat [Tyr’]CGRP (0). human [Tyr’]CGRP (A), salmon CT (0) and human CT (+) (A), and rat 
[Tyr’]CGRP-(28-37) (v), rat CGRP (0) and rat CGRP plus I PM rat [Tyr’]CGRP-(28-37) (w) (B). Basal cyclic AMP level in (A) 
and (B) was 0.31 + 0.03 nmol/mg of protein. Values are means + SE of independent experiments. 
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rat brain and heart [ 131, human cerebellum [ 141 
and porcine spinal cord and heart ventricle [ 15,161. 
CGRP-mediated cyclic AMP stimulation has been 
reported for rat aortic smooth muscle cells [ 171, rat 
osteosarcoma UMR 106-01 cells [18], bovine en- 
dothelial cells [19] and in membranes of rat spleen, 
liver and atria1 myocytes [20-221. In contrast, 
high-affinity CGRP receptors were reported to be 
ineffective in activating adenylate cyclase in rat 
brain and spinal cord membranes [a]. Hence 
WE-68 is the first human, neural differentiated cell 
line displaying CGRP receptors functionally 
coupled to cyclic AMP accumulation. Human 
CGRP-II was the most potent of CGRPs studied 
indicating that WE-68 CGRP receptor specifically 
recognizes CGRP-II. Interestingly, CGRP-II but 
not CGRP-I mRNA has been detected in four of 
six Ewing’s sarcoma cell lines studied by Hoppener 
et al. [23] and CGRP-II was found to be secreted 
by one of these cells lines, IARC/EW-1. The C- 
terminal fragment [Tyr’]CGRP-(28-37), slightly 
capable of displacing radioligand, was functionally 
inactive suggesting that the N-terminal portion of 
CGRP is essential for adequate binding and 
eliciting a biological response in WE-68 cells. 
In conclusion, CGRP receptors are positively 
linked to cyclic AMP production in Ewing’s sar- 
coma cells. CGRP must be added to the list of 
neurohormones that modulate cyclic AMP genera- 
tion in WE-68, a human bone tumor cell line with 
neural differentiation characteristics [8,10,11]. 
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